Log in

Relevant bibliographies by topics / Pertussis / Journal articles

Journal articles on the topic 'Pertussis'

To see the other types of publications on this topic, follow the link: Pertussis.

Author: Grafiati

Published: 4 June 2021

Last updated: 14 March 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pertussis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Schneider, Ferenc, Éva Stánitz, Judit Kalácska, Tünde Tompity, and Beáta Gábor. "Whooping cough in an urban high school in Hungary. Conclusions of a local pertussis outbreak." Orvosi Hetilap 150, no. 33 (August 1, 2009): 1557–61. http://dx.doi.org/10.1556/oh.2009.28655.

Full text

Abstract:

A pertussis a védőoltás bevezetésével fokozatosan visszaszoruló fertőző betegség lett, de teljes eradikációja nem lehetséges. Ezt mutatják a nemzetközi és a hazai adatok is. Az ezredforduló után a pertussisos megbetegedések lassú növekedése figyelhető meg. Célkitűzés: Az adolescens pertussis klinikumának bemutatása egy helyi járvány kapcsán, ezzel egyidejűleg a pertussis jelenlétének demonstrálása a hazai populációban. Módszer: Az első felismert 18 éves beteg környezetében retrospektív adatgyűjtéssel felderített, tartósan köhögő betegektől vett vérmintából emelkedő pertussis-antitoxin-IgG meghatározásával igazolták a pertussisetiológiát. Eredmények: A járványügyi munka 17 további, szerológiai vizsgálattal megerősített megbetegedést derített fel a felismert beteg környezetében. Következtetések: Tartós köhögés hátterében pertussist kell keresni. A védőoltással szerzett pertussis elleni immunitás a gyermekkor végére kialszik, a kórokozó a hazai populációban is cirkulál, a pertussisemlékeztető oltás beillesztése a 11 éves korúak oltásába indokolt. Serdülő- és felnőttkorban a pertussis enyhébben és atípusosan zajlik, de elhúzódó köhögés esetén gondolni kell rá.

APA, Harvard, Vancouver, ISO, and other styles

2

Tjahjowargo, Sendy, and Hartono Gunardi. "Perbandingan Efektivitas dan Keamanan Vaksin Pertusis Aselular dan Whole-cell." Sari Pediatri 18, no. 5 (March 29, 2017): 403. http://dx.doi.org/10.14238/sp18.5.2017.403-8.

Full text

Abstract:

Latar belakang. Imunisasi merupakan upaya pencegahan terbaik terhadap berbagai penyakit infeksi. Vaksin difteri, tetanus, pertusis whole-cell (DTwP) dapat menimbulkan kejadian ikutan pasca imunisasi (KIPI) yang mengkhawatirkan orangtua. Vaksin difteri, tetanus, pertusis aselular (DTaP) memiliki KIPI lebih ringan, tetapi diduga kurang efektif. Tujuan. Mengetahui efektivitas vaksin DTaP dibandingkan dengan vaksin DTwP.Metode. Penelusuran literatur elektronik PubMed dan Cochrane dengan kata kunci “DTaP/acellular pertussis”, “DTwP/whole-cell pertussis”, “children”, “pertussis”, “vaccine” and “safety/efficacy/effectiveness” dalam 10 tahun terakhir (2006 – 2016). Hasil. Terdapat dua studi meta-analisis yang membandingkan efektivitas pemberian imunisasi DTwP dan DTaP serta satu studi kasus terkontrol yang membandingkan efek perlindungan jangka panjang pemberian imunisasi DTaP dengan DTwP. Efektivitas vaksin pertusis aselular berkisar 74% (IK95%, 51–86%) – 97% (IK95%, 91–99%). Efektivitas vaksin pertusis whole-cell sebesar 94% (IK95%, 88–97%; p<0,0001). Estimasi effect size vaksin pertusis aseluer untuk melindungi terhadap penyakit pertusis sesuai kriteria WHO adalah sebesar 84% (IK95%, 81–87%); sedangkan untuk vaksin pertusis whole cell adalah 94% (IK95%, 88–97%). KIPI vaksin DTaP lebih ringan dan jarang dibandingkan vaksin DTwPKesimpulan. Vaksin DTaP dan DTwP mempunyai efektivitas yang sebanding. Vaksin DTwP mempunyai effect size yang lebih besar untuk melindungi terhadap penyakit pertusis dan perlindungan jangka panjang yang lebih baik dibandingkan vaksin DTaP. Vaksin DTaP mempunyai KIPI yang lebih ringan dan jarang dibandingkan vaksin DTwP.

APA, Harvard, Vancouver, ISO, and other styles

3

Zadorozhnaya, V. I., A. P. Podavalenko, and N. I. Operchuk. "Risk of an Intensification of Pertussis Epidemic and its Vaccinal Prevention Process in Ukraine." Epidemiology and Vaccine Prevention 14, no. 1 (February 20, 2015): 78–82. http://dx.doi.org/10.31631/2073-3046-2015-14-1-78-82.

Full text

Abstract:

The pertussis epidemic process is characterized by cyclical ups 2-5 years, high level of child and town population morbidity. Longterm pertussis morbidity dynamics in Ukraine tends to increase. Low coverage of a pertusiss immunization of the children's population, increase of immunocompromised individuals in the population, deterioration of social, economic and ecological factors are adverse conditions for a current of the pertussis epidemic process. The first priority is to maintain an appropriate level of routine immunization of children with increased attention to immunocompromised persons.

APA, Harvard, Vancouver, ISO, and other styles

4

Kilgore, Paul E., Abdulbaset M. Salim, Marcus J. Zervos, and Heinz-Josef Schmitt. "Pertussis: Microbiology, Disease, Treatment, and Prevention." Clinical Microbiology Reviews 29, no. 3 (March 30, 2016): 449–86. http://dx.doi.org/10.1128/cmr.00083-15.

Full text

Abstract:

SUMMARYPertussis is a severe respiratory infection caused byBordetella pertussis, and in 2008, pertussis was associated with an estimated 16 million cases and 195,000 deaths globally. Sizeable outbreaks of pertussis have been reported over the past 5 years, and disease reemergence has been the focus of international attention to develop a deeper understanding of pathogen virulence and genetic evolution ofB. pertussisstrains. During the past 20 years, the scientific community has recognized pertussis among adults as well as infants and children. Increased recognition that older children and adolescents are at risk for disease and may transmitB. pertussisto younger siblings has underscored the need to better understand the role of innate, humoral, and cell-mediated immunity, including the role of waning immunity. Although recognition of adult pertussis has increased in tandem with a better understanding ofB. pertussispathogenesis, pertussis in neonates and adults can manifest with atypical clinical presentations. Such disease patterns make pertussis recognition difficult and lead to delays in treatment. Ongoing research using newer tools for molecular analysis holds promise for improved understanding of pertussis epidemiology, bacterial pathogenesis, bioinformatics, and immunology. Together, these advances provide a foundation for the development of new-generation diagnostics, therapeutics, and vaccines.

APA, Harvard, Vancouver, ISO, and other styles

5

Conly, John M., and B. Lynn Johnston. "The Role of the Aceullular Pertussis Vaccine and the Comeback of 'Pertussis Pete'?" Canadian Journal of Infectious Diseases 12, no. 1 (2001): 15–17. http://dx.doi.org/10.1155/2001/839183.

Full text

Abstract:

Pertussis or whooping cough is an acute infectious disease of the respiratory tract caused principally byBordetella pertussisand less commonly byBordetella parapertussis(1). Until two decades ago, pertussis in adults was a medical curiosity (2-4), but with the purification of specificBordetellaspecies antigens, the development of reliable enzyme immunoassays allowing accurate serological diagnosis and better understanding of the duration of immunity from vaccination, it has been clearly demonstrated thatB pertussisis a common cause of prolonged cough in adults. Indeed, its incidence has been increasing gradually over the past decade in both adults and adolescents. Given the recognition of the importance of pertussis as a cause of prolonged cough in adults and the advent of the new acellular pertussis vaccines, it is timely to review current concepts of the pathogenesis of pertussis, its epidemiology in adults and the utility of the anticipated impact of the acellular vaccine.

APA, Harvard, Vancouver, ISO, and other styles

6

Daniels, Heather L., and Camille Sabella. "Bordetella pertussis (Pertussis)." Pediatrics in Review 39, no. 5 (May 2018): 247–57. http://dx.doi.org/10.1542/pir.2017-0229.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pascual, F. Brian, Candace L. McCall, Aaron McMurtray, Tony Payton, Forrest Smith, and Kristine M. Bisgard. "Outbreak of Pertussis Among Healthcare Workers in a Hospital Surgical Unit." Infection Control & Hospital Epidemiology 27, no. 6 (June 2006): 546–52. http://dx.doi.org/10.1086/506232.

Full text

Abstract:

Background.In September 1999, a pertussis outbreak was detected among surgical staff of a 138-bed community hospital. Patients were exposed toBordetella pertussisduring the 3-month outbreak period.Objective.To describe the outbreak among surgical staff, to evaluate implemented control measures, and to determine whether nosocomial transmission occurred.Methods.Clinical pertussis was defined as acute cough illness with a duration of 14 days or more without another apparent cause; persons with positive culture, PCR, or serologic test results were defined as having laboratory-confirmed pertussis. Surgical healthcare workers (HCWs) were interviewed regarding pertussis symptoms, and specimens were obtained for laboratory analysis. Patients exposed toB. pertussisduring an ill staff member's 3-week infectious period were interviewed by phone to determine the extent of nosocomial spread.Participants.A total of 53 HCWs assigned to the surgical unit and 146 exposed patients. HCWs with pertussis were defined as case subjects; HCWs without pertussis were defined as non-case subjects.Results.Twelve (23%) of 53 HCWs had clinical pertussis; 6 cases were laboratory confirmed. The median cough duration in the 12 case subjects was 27 days (range, 20-120 days); 10 (83%) had paroxysms. Eleven (92%) of 12 case subjects and 28 (86%) of 41 non-case subjects received antibiotic treatment or prophylaxis. Seven case subjects (58%) reported they always wore a mask when near patients. Of 146 patients potentially exposed to pertussis from the 12 case subjects, 120 (82%) were interviewed; none reported a pertussis-like illness.Conclusions.Surgical staff transmittedB. pertussisamong themselves; self-reported data suggests that these HCWs did not transmitB. pertussisto their patients, likely because of mask use, cough etiquette, and limited face-to-face contact. Control measures might have helped limit the outbreak once pertussis was recognized.

APA, Harvard, Vancouver, ISO, and other styles

8

Kandola, Kami, Amy Lea, Wanda White, and Maria Santos. "A Comparison of Pertussis Rates in the Northwest Territories: Pre- and Postacellular Pertussis Vaccine Introduction in Children and Adolescents." Canadian Journal of Infectious Diseases and Medical Microbiology 16, no. 5 (2005): 271–74. http://dx.doi.org/10.1155/2005/642315.

Full text

Abstract:

INTRODUCTION: During the past decade, a trend toward increasing cases ofBordetella pertussisin older children and adults has been witnessed in Canada. The National Advisory Committee on Immunization now recommends that the adult formulation of the acellular pertussis (adult dTap) vaccine combined with diphtheria and tetanus toxoids be substituted for diphtheria and tetanus toxoids alone for the 14- to 16-year-old booster dose. In October 2000, the government of the Northwest Territories was one of the first to adopt adult dTap into their territorial immunization program free of charge.OBJECTIVE: To evaluate the effect of the acellular pertussis vaccine in children and adolescents on the epidemiology of pertussis in the Northwest Territories.METHODS: Pertussis is a reportable disease in the Northwest Territories, and data on the incidence rates of pertussis are available from 1989 to 2004. The present study reviews pertussis cases during three four-year periods: the whole-cell vaccine era (1993 to 1996); the preadult dTap era (1997 to 2000); and the postadult dTap era (2001 to 2004).RESULTS: The incidence of pertussis decreased from 18.0 cases per 10,000 population in 1993 to 0.2 cases per 10,000 population in 2004. The number of cases decreased from 186 to 129 to 19 cases in the three chronological time periods (ie, whole-cell vaccine era, preadult dTap era and postadult dTap era, respectively), with the most substantial reduction coming with the introduction of postadult dTap.CONCLUSIONS: There appears to be a decrease in the incidence of pertussis with the targeted introduction of adult dTap in the Northwest Territories.

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Xuqing, Sara E. Hester, Mary J. Kennett, Alexia T. Karanikas, Liron Bendor, David E. Place, and Eric T. Harvill. "Interleukin-1 Receptor Signaling Is Required To Overcome the Effects of Pertussis Toxin and for Efficient Infection- or Vaccination-Induced Immunity againstBordetella pertussis." Infection and Immunity 79, no. 1 (October 25, 2010): 527–41. http://dx.doi.org/10.1128/iai.00590-10.

Full text

Abstract:

ABSTRACTInterleukin-1 receptor-deficient (IL-1R−/−) mice are healthy despite being colonized by commensal microbes but are defective in defenses against specific pathogens, suggesting that IL-1R-mediated effects contribute to immune responses against specific pathogenic mechanisms. To better define the role of IL-1R in immunity to respiratory infections, we challenged IL-1R−/−mice withBordetella pertussisandBordetella parapertussis, the causative agents of whooping cough. Following inoculation withB. pertussis, but notB. parapertussis, IL-1R−/−mice showed elevated bacterial numbers and more extensive inflammatory pathology than wild-type mice. AcellularB. pertussisvaccines were not efficiently protective againstB. pertussisin IL-1R−/−mice.B. pertussis-stimulated dendritic cells from IL-1R−/−mice produced higher levels of tumor necrosis factor alpha (TNF-α) and IL-6 than wild-type cells. Moreover, elevated levels of gamma interferon (IFN-γ) and TNF-α but lower levels of IL-10 were detected duringB. pertussisinfection in IL-1R−/−mice. SinceB. parapertussisdid not cause severe disease in IL-1R−/−mice, we hypothesized that the extreme requirement for IL-1R involves pertussis toxin (Ptx), which is expressed only byB. pertussis. An isogenic Ptx-deficientB. pertussisstrain had only a modest phenotype in wild-type mice but was completely defective in causing lethal disease in IL-1R−/−mice, indicating that the particular virulence ofB. pertussisin these mice requires Ptx. Ptx contributes to IL-1β induction byB. pertussis, which is involved in IL-10 induction through IL-1R signaling. IL-10 treatment reducedB. pertussisnumbers in IL-1R−/−mice, suggesting that the lower IL-10 responses partially account for the uncontrolled inflammation and bacterial growth in these mice.

APA, Harvard, Vancouver, ISO, and other styles

10

Aase, Audun, Tove Karin Herstad, Samuel Merino, Merete Bolstad, Synne Sandbu, Hilde Bakke, and Ingeborg S. Aaberge. "Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity." Clinical and Vaccine Immunology 18, no. 8 (June 15, 2011): 1269–74. http://dx.doi.org/10.1128/cvi.05067-11.

Full text

Abstract:

ABSTRACTWaning vaccine-induced immunity againstBordetella pertussisis observed among adolescents and adults. A high incidence of pertussis has been reported in this population, which serves as a reservoir forB. pertussis. A fifth dose of reduced antigen of diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine was given as a booster dose to healthy teenagers. The antibody activity againstB. pertussisantigens was measured prior to and 4 to 8 weeks after the booster by different assays: enzyme-linked immunosorbent assays (ELISAs) of IgG and IgA against pertussis toxin (PT) and filamentous hemagglutinin (FHA), IgG against pertactin (PRN), opsonophagocytic activity (OPA), and IgG binding to liveB. pertussis. There was a significant increase in the IgG activity against PT, FHA, and PRN following the booster immunization (P< 0.001). The prebooster sera showed a geometric mean OPA titer of 65.1 and IgG binding to live bacteria at a geometric mean concentration of 164.9 arbitrary units (AU)/ml. Following the fifth dose, the OPA increased to a titer of 360.4, and the IgG concentration against live bacteria increased to 833.4 AU/ml (P< 0.001 for both). The correlation analyses between the different assays suggest that antibodies against FHA and PRN contribute the most to the OPA and IgG binding.

APA, Harvard, Vancouver, ISO, and other styles

11

Pichichero, Michael E. "Pertussis and the pertussis vaccines." Current Opinion in Infectious Diseases 6, no. 4 (August 1993): 558–64. http://dx.doi.org/10.1097/00001432-199308000-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Handayani, Sarwo. "Profil Kekebalan Terhadap Difteri, Pertusis dan Tetanus pada Anak Umur di Bawah Lima Tahun, Hasil Riskesdas 2013." Buletin Penelitian Kesehatan 47, no. 3 (December 20, 2019): 183–90. http://dx.doi.org/10.22435/bpk.v47i3.1503.

Full text

Abstract:

Children under five years are a vulnerable group for diseases infection, therefore immunity to vaccine preventable diseases are essential, such as diphtheria, pertussis and tetanus. Those mentioned diseases, immunization is the most effective effort to reduce the mortality and morbidity. As a part of Basic Health Research analysis for samples collected in 2013, sera of 368 children under five years (aged 12-59 months) were tested for IgG to diphtheria, pertussis toxin and tetanus by ELISA method. The proportion of protective antibody associated with DPT immunization status obtained by univariate analysis. Based on health record and questionnaire, only 72% children under five years received a complete 3-dose of DPT vaccine. Fully protective immunity to diphtheria and tetanus (titer ≥ 0.1 IU / ml) were only found 70% and 83% of children under five years with a complete DPT immunization status, respectively. Very small proportion (0.27%) of children without immunity to diphtheria and tetanus (titer <0.01 IU / ml) were observed. Results showed less than 10% children under five years had immunity to pertussis toxin, indicated that the pertussis exposure occurred within 12 months. Incomplete immunization status and high proportion of negative titers especially for pertussis toxin, should have attention exclusively for the completeness of recording and immunization card and also the vaccine storage. Furthermore, the immunization booster should be administered to provide long protective immunity. Keywords: immunity, DPT, under five years, ELISA Abstrak Balita merupakan kelompok rentan yang perlu mendapatkan perhatian, terutama kekebalan terhadap penyakit yang dapat dicegah dengan imunisasi, antara lain difteri, pertussis dan tetanus. Imunisasi merupakan upaya yang paling efektif untuk menurunkan angka kematian dan kesakitan karena penyakit tersebut. Sebanyak 368 sampel darah balita (umur 12- 59 bulan), bagian dari sampel Riset Kesehatan Dasar tahun 2013 telah diperiksa kekebalan terhadap difteri, pertusis toksin dan tetanus dengan metode ELISA. Analisis data secara deskriptif berupa proporsi kekebalan protektif dari masing-masing parameter dikaitkan dengan status imunisasi DPT. Berdasarkan hasil observasi catatan kesehatan dan wawancara menunjukkan hanya 72% balita yang mendapat imunisasi DPT lengkap 3 dosis. Kekebalan protektif difteri dan tetanus dengan titer ≥ 0,1 IU/ml hanya dimiliki sekitar 70% dan 83% balita dengan status imunisasi DPT lengkap. Walaupun proporsinya sangat kecil (0,27%), masih ditemukan balita yang tidak mempunyai kekebalan terhadap difteri dan tetanus (titer <0,01 IU/ml). Kurang dari 10% balita memiliki kekebalan terhadap pertusis toksin dengan keterpaparan dalam jangka waktu 12 bulan. Ditemukannya balita dengan status imunisasi yang tidak lengkap dan titer negatif yang cukup tinggi terutama terhadap pertussis toksin, perlu mendapat perhatian yang serius, terutama kelengkapan pencatatan dan kartu imunisasi serta penyimpanan vaksin, Pemberian booster imunisasi perlu dilakukan untuk memberikan kekebalan yang penuh dalam jangka panjang. Kata kunci: kekebalan, DPT, balita, ELISA

APA, Harvard, Vancouver, ISO, and other styles

13

Burnett, Mark W. "Pertussis." Journal of Special Operations Medicine 13, no. 4 (2013): 113. http://dx.doi.org/10.55460/nb14-jh4h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ang, Brenda. "Pertussis." Singapore Family Physician 45, no. 4 (May 1, 2019): 15–17. http://dx.doi.org/10.33591/sfp.45.4.u3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Tompkins, Olga S. "Pertussis." AAOHN Journal 59, no. 6 (June 1, 2011): 276. http://dx.doi.org/10.3928/08910162-20110525-04.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Galiza, Eva P., Anna Calvert, Simon B. Drysdale, and Paul T. Heath. "Pertussis." Medicine 49, no. 12 (December 2021): 739–42. http://dx.doi.org/10.1016/j.mpmed.2021.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Saks, Mark. "Pertussis." Emergency Medicine News 28, no. 6 (June 2006): 13–14. http://dx.doi.org/10.1097/00132981-200606000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Liese, J. "Pertussis." Kinder- und Jugendmedizin 11, no. 03 (2011): 144–46. http://dx.doi.org/10.1055/s-0038-1629134.

Full text

Abstract:

ZusammenfassungPertussis, die häufigste Form des Keuchhus-tens, ist eine Infektionskrankheit des Respirationstraktes, die durch Bordetella pertussis verursacht wird. In ungeimpften Populationen tritt Pertussis überwiegend im Alter zwischen zwei und sechs Jahren auf. In Populationen mit einer hohen Pertussis-Durchimpfungsrate im Kindesalter wird eine Verschiebung von Pertussiserkrankungen in das Adoleszentenund Erwachsenenalter beobachtet. Dadurch entstehen neue Übertragungswege auf junge, oft ungeimpfte Säuglinge. Diese wiederum haben das höchste Risiko für einen schweren Verlauf der Pertussiserkrankung mit erhöhtem Mortalitätsrisiko, z. B. durch Apnoen. Neue Strategien mit einer Ausdehnung der Pertussis-Impfprävention in das Jugend-lichen- und Erwachsenenalter tragen den Veränderungen in der Epidemiologie Rechnung.

APA, Harvard, Vancouver, ISO, and other styles

19

Chiocca, Ellen M. "Pertussis." Nursing 36, no. 7 (July 2006): 72. http://dx.doi.org/10.1097/00152193-200607000-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Heath, Paul T., and Louise A. Denvir. "Pertussis." Medicine 29, no. 3 (2001): 91–93. http://dx.doi.org/10.1383/medc.29.3.91.27599.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sinha, Ruchi, and Paul T. Heath. "Pertussis." Medicine 33, no. 5 (May 2005): 101–2. http://dx.doi.org/10.1383/medc.33.5.101.64962.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Andersen, Erin. "Pertussis." AAOHN Journal 52, no. 12 (December 2004): 498–99. http://dx.doi.org/10.1177/216507990405201202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Olga, S. Tompkins. "Pertussis." AAOHN Journal 59, no. 6 (June 2011): 276. http://dx.doi.org/10.1177/216507991105900606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Heininger, Ulrich. "Pertussis." Pediatric Infectious Disease Journal 31, no. 1 (January 2012): 78–79. http://dx.doi.org/10.1097/inf.0b013e31823b034e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Galiza, Eva P., and Paul T. Heath. "Pertussis." Medicine 37, no. 12 (December 2009): 635–37. http://dx.doi.org/10.1016/j.mpmed.2009.09.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kent, Alison, and Paul T. Heath. "Pertussis." Medicine 42, no. 1 (January 2014): 8–10. http://dx.doi.org/10.1016/j.mpmed.2013.10.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Calvert, Anna, and Paul T. Heath. "Pertussis." Medicine 45, no. 12 (December 2017): 735–38. http://dx.doi.org/10.1016/j.mpmed.2017.09.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Nguyen, Van Tuong Ngoc, and Lauren Simon. "Pertussis." Primary Care: Clinics in Office Practice 45, no. 3 (September 2018): 423–31. http://dx.doi.org/10.1016/j.pop.2018.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Schweon, Steven J. "Pertussis." Nursing 41, no. 10 (October 2011): 61–62. http://dx.doi.org/10.1097/01.nurse.0000405118.16392.86.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Spector, Tara B., and Eileen K. Maziarz. "Pertussis." Medical Clinics of North America 97, no. 4 (July 2013): 537–52. http://dx.doi.org/10.1016/j.mcna.2013.02.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Leber, Amy L. "Pertussis." Clinics in Laboratory Medicine 34, no. 2 (June 2014): 237–55. http://dx.doi.org/10.1016/j.cll.2014.02.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Weisberg, Susan Shoshana. "Pertussis." Disease-a-Month 53, no. 10 (October 2007): 488–94. http://dx.doi.org/10.1016/j.disamonth.2007.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Weinstein, Robert. "Pertussis." Infection Control & Hospital Epidemiology 11, no. 5 (May 1990): 268. http://dx.doi.org/10.1017/s0899823x00083148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Gabutti, Giovanni, Chiara Azzari, Paolo Bonanni, Rosa Prato, Alberto E. Tozzi, Alessandro Zanetti, and Gianvincenzo Zuccotti. "Pertussis." Human Vaccines & Immunotherapeutics 11, no. 1 (November 2014): 108–17. http://dx.doi.org/10.4161/hv.34364.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Jakinovich, Andrea, and Sunil K. Sood. "Pertussis." Current Opinion in Pediatrics 26, no. 5 (October 2014): 597–604. http://dx.doi.org/10.1097/mop.0000000000000139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Kadin, M. "Pertussis." ASH Image Bank 2003, no. 0507 (May 7, 2003): 100701. http://dx.doi.org/10.1182/ashimagebank-2003-100701.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Lazarchick, J. "Pertussis." ASH Image Bank 2005, no. 0325 (March 25, 2005): 101340. http://dx.doi.org/10.1182/ashimagebank-2005-101340.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

MATHIS, ROBERT D., BARBARA SHOAF, and TRACY I. WEINER. "Pertussis." Pediatric Emergency Care 9, no. 4 (August 1993): 218–20. http://dx.doi.org/10.1097/00006565-199308000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Heininger, U. "Pertussis." Monatsschrift Kinderheilkunde 164, no. 11 (September 16, 2016): 987–93. http://dx.doi.org/10.1007/s00112-016-0158-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Plotkin, Stanley A. "Pertussis." Vaccine 7, no. 3 (June 1989): 195. http://dx.doi.org/10.1016/0264-410x(89)90227-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Pluta, Ryszard M. "Pertussis." JAMA 304, no. 8 (August 25, 2010): 922. http://dx.doi.org/10.1001/jama.304.8.922.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Guiso, N., and D. Hozbor. "Bordetella pertussis Polymorphism and Pertussis Vaccines." Clinical and Vaccine Immunology 15, no. 2 (February 1, 2008): 394–95. http://dx.doi.org/10.1128/cvi.00391-07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hong, Jung Yun. "Update on pertussis and pertussis immunization." Korean Journal of Pediatrics 53, no. 5 (2010): 629. http://dx.doi.org/10.3345/kjp.2010.53.5.629.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Herwaldt, Lorween A. "Pertussis and Pertussis Vaccines in Adults." JAMA: The Journal of the American Medical Association 269, no. 1 (January 6, 1993): 93. http://dx.doi.org/10.1001/jama.1993.03500010103042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Herwaldt, L. A. "Pertussis and pertussis vaccines in adults." JAMA: The Journal of the American Medical Association 269, no. 1 (January 6, 1993): 93–94. http://dx.doi.org/10.1001/jama.269.1.93.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Fadugba, Olajumoke O., Li Wang, Qingxia Chen, and Natasha B. Halasa. "Immune Responses to Pertussis Antigens in Infants and Toddlers after Immunization with Multicomponent Acellular Pertussis Vaccine." Clinical and Vaccine Immunology 21, no. 12 (September 24, 2014): 1613–19. http://dx.doi.org/10.1128/cvi.00438-14.

Full text

Abstract:

ABSTRACTGiven the resurgence of pertussis despite high rates of vaccination with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine, a better understanding of vaccine-induced immune responses toBordetella pertussisis needed. We investigated the antibody, cell-mediated, and cytokine responses toB. pertussisantigens in children who received the primary vaccination series (at 2, 4, and 6 months) and first booster vaccination (at 15 to 18 months) with 5-component acellular pertussis (aP) vaccine. The majority of subjects demonstrated a 4-fold increase in antibody titer to all four pertussis antigens (pertussis toxin [PT], pertactin [PRN], filamentous hemagglutinin [FHA], and fimbriae [FIM]) following the primary series and booster vaccination. Following the primary vaccine series, the majority of subjects (52 to 67%) mounted a positive T cell proliferative response (stimulation index of ≥3) to the PT and PRN antigens, while few subjects (7 to 12%) mounted positive proliferative responses to FHA and FIM. One month after booster vaccination (age 16 to 19 months), our study revealed significant increase in gamma interferon (IFN-γ) production in response to the PT and FIM antigens, a significant increase in IL-2 production with the PT, FHA, and PRN antigens, and a lack of significant interleukin-4 (IL-4) secretion with any of the antigens. While previous reports documented a mixed Th1/Th2 or Th2-skewed response to DTaP vaccine in children, our data suggest that following the first DTaP booster, children aged 16 to 19 months have a cytokine profile consistent with a Th1 response, which is known to be essential for clearance of pertussis infection. To better define aP-induced immune responses following the booster vaccine, further studies are needed to assess cytokine responses pre- and postbooster in DTaP recipients.

APA, Harvard, Vancouver, ISO, and other styles

47

Hanawa, Tomoko, Kazunari Kamachi, Hideo Yonezawa, Toshiyuki Fukutomi, Hayato Kawakami, and Shigeru Kamiya. "Glutamate Limitation, BvgAS Activation, and (p)ppGpp Regulate the Expression of the Bordetella pertussis Type 3 Secretion System." Journal of Bacteriology 198, no. 2 (November 2, 2015): 343–51. http://dx.doi.org/10.1128/jb.00596-15.

Full text

Abstract:

ABSTRACTBordetella pertussisis a bacterium that is considered to be highly adapted to humans, and it has not been isolated from the environment. As this bacterium does not utilize sugars, the abundant supply of glutamate in Stainer Scholte (SS) medium enablesB. pertussisto grow efficiently in liquid culturein vitro, and as such, SS medium is a popular choice for laboratory experiments. However, the concentration of glutamate in thein vivoniche ofB. pertussisis quite low. We investigated the bacterial response to low concentrations of glutamate to elucidate bacterial physiology via the expression of the type 3 secretion system (T3SS), and we discuss its relationship to the Bvg mode in which the two-component regulator of pathogenesis (BvgAS) is activated. Glutamate limitation induced the expression of both the T3SS apparatus and effector genes at the transcriptional level. (p)ppGpp, a modulator of the stringent response, was necessary for maximum expression of the T3SS genes. These observations indicate that the expression of the T3SS is managed by nutrient starvation. In addition, the autoaggregation ability was high in the absence of glutamate and no autoaggregation was observed in glutamate-replete medium. Taken together, glutamate-limited conditions in Bvg+mode elicit the high expression of T3SS genes inB. pertussisand promotes its sessile form.IMPORTANCEBordetella pertussisis a highly contagious pathogen that causes respiratory infectious disease. In spite of the increasing use of vaccination, the number of patients with pertussis is increasing. The proteins producedin vivooften are different from the protein profile under laboratory conditions; therefore, the development of conditions reflecting the host environment is important to understand native bacterial behavior. In the present study, we examined the effect of glutamate limitation, as its concentrationin vivois much lower than that in the culture medium currently used forB. pertussisexperiments. As predicted, the T3SS was induced by glutamate limitation. These results are suggestive of the importance of regulation by nutrient conditions and in the pathogenicity ofB. pertussis.

APA, Harvard, Vancouver, ISO, and other styles

48

Burgos-Rivera, Brunilís, Adria D. Lee, Katherine E. Bowden, Amanda E. Faulkner, Brent L. Seaton, Bryndon D. Lembke, Charles P. Cartwright, Stacey W. Martin, and M. Lucia Tondella. "Evaluation of Level of Agreement in Bordetella Species Identification in Three U.S. Laboratories during a Period of Increased Pertussis." Journal of Clinical Microbiology 53, no. 6 (March 25, 2015): 1842–47. http://dx.doi.org/10.1128/jcm.03567-14.

Full text

Abstract:

While PCR is the most common method used for detectingBordetella pertussisin the United States, most laboratories use insertion sequence481(IS481), which is not specific forB. pertussis; therefore, the relative contribution of otherBordetellaspecies is not understood. The objectives of this study were to evaluate the proportion of otherBordetellaspecies misidentified asB. pertussisduring a period of increased pertussis incidence, determine the level of agreement inBordetellaspecies detection between U.S. commercial laboratories and the CDC, and assess the relative diagnostic sensitivity of CDC's PCR assay when using a different PCR master mix. Specimens collected between May 2012 and May 2013 were tested at two U.S. commercial laboratories forB. pertussisandB. parapertussisdetection. Every fifth specimen positive for IS481and/or IS1001with cycle threshold (CT) values of ≤35 was sent to CDC for PCR testing that identifiesBordetellaspecies. Specimens with indeterminate or negative results in the CDC PCR were tested using an alternate PCR master mix. Of 755 specimens, there was agreement in species identification for 83.4% (n= 630). Of the specimens with different identifications (n= 125), 79.2% (n= 99) were identified as indeterminateB. pertussisat CDC. Overall, 0.66% (n= 5) of the specimens were identified asB. holmesiiorB. bronchisepticaat CDC. Of 115 specimens with indeterminate or negative results, 46.1% (n= 53) wereB. pertussispositive when tested by an alternate master mix, suggesting a possible increase in assay sensitivity. This study demonstrates good agreement between the two U.S. commercial laboratories and CDC and little misidentification ofBordetellaspecies during the 2012 U.S. epidemic.

APA, Harvard, Vancouver, ISO, and other styles

49

Burns, Drusilla L. "Secretion of Pertussis Toxin from Bordetella pertussis." Toxins 13, no. 8 (August 18, 2021): 574. http://dx.doi.org/10.3390/toxins13080574.

Full text

Abstract:

Production and secretion of pertussis toxin (PT) is essential for the virulence of Bordetella pertussis. Due to the large oligomeric structure of PT, transport of the toxin across bacterial membrane barriers represents a significant hurdle that the bacteria must overcome in order to maintain pathogenicity. During the secretion process, PT undergoes a two-step transport process. The first step involves transport of the individual polypeptide chains of PT across the inner membrane utilizing a generalized secretion pathway, most likely the bacterial Sec system. The second step involves the use of a specialized apparatus to transport the toxin across the outer membrane of the bacterial cell. This apparatus, which has been termed the Ptl transporter and which is unique to the PT secretion pathway, is a member of the type IV family of bacterial transporters. Here, the current understanding of the PT secretion process is reviewed including a description of the Ptl proteins that assemble to form the transporter, the general structure of type IV transporters, the known similarities and differences between canonical type IV substrate transport and Ptl-mediated transport of PT, as well as the known sequence of events in the assembly and secretion of PT.

APA, Harvard, Vancouver, ISO, and other styles

50

Shah, Raju C., and Anuj R. Shah. "Pertussis vaccine controversies and acellular pertussis vaccine." Indian Journal of Pediatrics 70, no. 6 (June 2003): 485–88. http://dx.doi.org/10.1007/bf02723139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!